Drugs / EDP-235
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05594602 | Oct → Dec 2022 | COVID-19 | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05594615 | Oct → Nov 2022 | COVID-19 | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT05246878 | Jan → Jul 2022 | COVID-19 | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05616728 | Nov 2022 → Feb 2023 | COVID-19 | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP-235 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05594615 ↗ |
| Route | Oral | “Oral administration” NCT05246878 ↗ |